• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy.

作者信息

Dahiya Saurabh, Luetkens Tim, Lutfi Forat, Avila Stephanie, Iraguha Thierry, Margiotta Philip, Hankey Kim G, Lesho Patricia, Law Jennie Y, Lee Seung T, Baddley John, Kocoglu Mehmet, Yared Jean A, Hardy Nancy M, Rapoport Aaron P, Atanackovic Djordje

机构信息

Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine and University of Maryland Medical System, Baltimore, MD; and.

Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD.

出版信息

Blood Adv. 2022 Jan 25;6(2):686-689. doi: 10.1182/bloodadvances.2021006112.

DOI:10.1182/bloodadvances.2021006112
PMID:34941995
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8709721/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecd3/8791592/4db793b8e4d2/advancesADV2021006112f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecd3/8791592/de36285e21bc/advancesADV2021006112f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecd3/8791592/4db793b8e4d2/advancesADV2021006112f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecd3/8791592/de36285e21bc/advancesADV2021006112f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecd3/8791592/4db793b8e4d2/advancesADV2021006112f2.jpg

相似文献

1
Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy.CD19嵌合抗原受体T细胞疗法后B细胞恶性肿瘤患者对新冠病毒疫苗接种的免疫反应受损。
Blood Adv. 2022 Jan 25;6(2):686-689. doi: 10.1182/bloodadvances.2021006112.
2
Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.抗 CD19 嵌合抗原受体 T 细胞诱导的 B 细胞发育不良的年轻患者对 SARS-CoV-2 疫苗的免疫反应。
Transplant Cell Ther. 2022 Jul;28(7):366.e1-366.e7. doi: 10.1016/j.jtct.2022.04.017. Epub 2022 Apr 26.
3
Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy.CD19嵌合抗原受体T细胞（CAR T）治疗后患者对SARS-CoV-2疫苗接种的细胞免疫和体液免疫反应
Blood Adv. 2023 May 23;7(10):2066-2069. doi: 10.1182/bloodadvances.2022007806.
4
Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.造血干细胞移植和嵌合抗原受体 T 细胞治疗受者对 SARS-CoV-2 疫苗接种的免疫反应。
J Hematol Oncol. 2022 Jun 16;15(1):81. doi: 10.1186/s13045-022-01300-9.
5
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey.SARS-CoV-2 疫苗接种和单克隆抗体对 CD19 导向的 CAR T 细胞治疗后结局的影响：一项 EPICOVIDEHA 调查。
Blood Adv. 2023 Jun 13;7(11):2645-2655. doi: 10.1182/bloodadvances.2022009578.
6
COVID-19 Vaccination and Anti-CD19 CAR T Cell-Induced B Cell Aplasia.新型冠状病毒肺炎疫苗接种与抗CD19嵌合抗原受体T细胞诱导的B细胞发育不全
Transplant Cell Ther. 2022 Aug;28(8):515. doi: 10.1016/j.jtct.2022.05.024. Epub 2022 May 19.
7
Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis.接受嵌合抗原受体T细胞疗法的B细胞血液系统恶性肿瘤患者接种多剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的疗效：一项当代队列分析
Transplant Cell Ther. 2024 Mar;30(3):285-297. doi: 10.1016/j.jtct.2023.12.011. Epub 2023 Dec 23.
8
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.异基因造血细胞移植或嵌合抗原受体 T 细胞治疗后第一年的 SARS-CoV-2 疫苗接种：一项前瞻性、多中心、观察性研究。
Clin Infect Dis. 2024 Aug 16;79(2):542-554. doi: 10.1093/cid/ciae291.
9
Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy.造血细胞移植和嵌合抗原受体T细胞疗法后患者对SARS-CoV-2疫苗接种的反应。
Blood. 2021 Oct 7;138(14):1278-1281. doi: 10.1182/blood.2021012769.
10
Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy.造血细胞移植和嵌合抗原受体 T 细胞治疗后对 SARS-CoV-2 疫苗的体液反应的预测因素。
Blood Cancer Discov. 2021 Sep 13;2(6):577-585. doi: 10.1158/2643-3230.BCD-21-0142. eCollection 2021 Nov.

引用本文的文献

1
Mannan-Decorated Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Antitumor Immune Response by Modulating the Tumor Microenvironment.甘露糖修饰的脂质磷酸钙纳米颗粒疫苗通过调节肿瘤微环境增强抗肿瘤免疫反应。
J Funct Biomater. 2024 Aug 16;15(8):229. doi: 10.3390/jfb15080229.
2
Severe acute respiratory syndrome coronavirus 2 infection in patients with hematological malignancies in the Omicron era: Respiratory failure, need for mechanical ventilation and mortality in seronegative and seropositive patients.奥密克戎时代血液系统恶性肿瘤患者的严重急性呼吸综合征冠状病毒2感染：血清阴性和血清阳性患者的呼吸衰竭、机械通气需求及死亡率
EJHaem. 2024 Apr 9;5(3):505-515. doi: 10.1002/jha2.867. eCollection 2024 Jun.
3

本文引用的文献

1
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma.BNT162b2 mRNA COVID-19 疫苗在 B 细胞非霍奇金淋巴瘤患者中的疗效。
Blood Adv. 2021 Aug 24;5(16):3053-3061. doi: 10.1182/bloodadvances.2021005094.
2
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study.异基因造血干细胞移植或基于 CD19 的嵌合抗原受体 T 细胞治疗后患者的 BNT162b2 mRNA COVID-19 疫苗的安全性和免疫原性：一项单中心前瞻性队列研究。
Transplant Cell Ther. 2021 Sep;27(9):788-794. doi: 10.1016/j.jtct.2021.06.024. Epub 2021 Jun 30.
3
Defibrotide improves COVID-19-related acute respiratory distress syndrome in myeloma patients after chimeric antigen receptor T-cell treatment without compromising virus-specific and anti-myeloma T-cell responses.
去纤苷可改善嵌合抗原受体T细胞治疗后骨髓瘤患者的COVID-19相关急性呼吸窘迫综合征，且不影响病毒特异性和抗骨髓瘤T细胞反应。
Haematologica. 2024 Jul 1;109(7):2372-2377. doi: 10.3324/haematol.2023.284793.
4
Outcomes and risk factors of SARS-CoV-2 omicron variant in B-cell lymphoma patients following CD19 targeted CAR-T therapy.COVID-19 奥密克戎变异株在接受 CD19 靶向嵌合抗原受体 T 细胞（CAR-T）治疗的 B 细胞淋巴瘤患者中的结局和风险因素。
Cancer Med. 2023 Nov;12(22):20838-20846. doi: 10.1002/cam4.6657. Epub 2023 Nov 14.
5
Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies.嵌合抗原受体 T 细胞免疫疗法治疗 T 细胞恶性肿瘤的进展与困境。
Transplant Cell Ther. 2024 Feb;30(2):171-186. doi: 10.1016/j.jtct.2023.10.013. Epub 2023 Oct 21.
6
Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry.嵌合抗原受体 T 细胞疗法治疗大 B 细胞淋巴瘤后的非复发死亡率：来自 DESCAR-T 登记处的 LYSA 研究。
Blood Adv. 2023 Nov 14;7(21):6589-6598. doi: 10.1182/bloodadvances.2023010624.
7
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies.嵌合抗原受体 (CAR) T 细胞疗法的感染性并发症。
Semin Hematol. 2023 Jan;60(1):52-58. doi: 10.1053/j.seminhematol.2023.02.003. Epub 2023 Mar 6.
8
Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.研究癌症患者接种第三和第四剂 COVID-19 疫苗的免疫反应效果和持久性：一项单臂临床试验。
Elife. 2023 Mar 28;12:e83694. doi: 10.7554/eLife.83694.
9
B-cell malignancies and COVID-19: a narrative review.B 细胞恶性肿瘤与 COVID-19：一篇叙述性综述。
Clin Microbiol Infect. 2023 Mar;29(3):332-337. doi: 10.1016/j.cmi.2022.10.030. Epub 2022 Nov 4.
10
Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology. 关于造血细胞移植和嵌合抗原受体 T 细胞受者的 2019 年冠状病毒病疫苗接种的常见问题解答（来自美国移植和细胞治疗学会与美国血液学会）。
Transplant Cell Ther. 2023 Jan;29(1):10-18. doi: 10.1016/j.jtct.2022.10.010. Epub 2022 Oct 21.
Human IgG and IgA responses to COVID-19 mRNA vaccines.
人类 IgG 和 IgA 对 COVID-19 mRNA 疫苗的反应。
PLoS One. 2021 Jun 16;16(6):e0249499. doi: 10.1371/journal.pone.0249499. eCollection 2021.
4
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients.血液系统恶性肿瘤合并 COVID-19 患者的结局：对 3377 例患者的系统评价和荟萃分析。
Blood. 2020 Dec 17;136(25):2881-2892. doi: 10.1182/blood.2020008824.
5
Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19.SARS-CoV-2 和 SARS-CoV 在人肺中的比较复制和免疫激活特征：一项具有 COVID-19 发病机制意义的离体研究。
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409. doi: 10.1093/cid/ciaa410.
6
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.SARS-CoV-2 刺突糖蛋白的特征及其对病毒进入的影响，以及与 SARS-CoV 的免疫交叉反应性。
Nat Commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9.
7
A pneumonia outbreak associated with a new coronavirus of probable bat origin.一种新型冠状病毒引发的肺炎疫情，该病毒可能来源于蝙蝠。
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
8
A Novel Coronavirus from Patients with Pneumonia in China, 2019.2019 年中国肺炎患者中的一种新型冠状病毒。
N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.
9
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.阿基仑赛注射液治疗难治性大 B 细胞淋巴瘤的长期安全性和疗效（ZUMA-1）：一项单臂、多中心、1-2 期临床试验。
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
10
Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor.一种使用 ACE2 受体的蝙蝠 SARS 样冠状病毒的分离与鉴定
Nature. 2013 Nov 28;503(7477):535-8. doi: 10.1038/nature12711. Epub 2013 Oct 30.